At Ansun, we are committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients.
DISCOVERING SOLUTIONS FOR THE WORLD.
The Latest Technology for
preventing and treating life-threatening human diseases.
Ansun is currently working with FDA to plan and implement a Phase 3 clinical trial of DAS181 for the treatment of PIV infection in hospitalized and immunocompromised patients.
DAS181 has received both Fast Track and Breakthrough Therapy designations by the U.S. FDA for this indication.
Ansun has observed activity of DAS181 against other important respiratory pathogens based on the same host-directed anti-viral mechanism.